FDA-approved drug may finally help immunotherapy defeat rare liver cancer

Scientists have discovered that a rare liver cancer tricks the immune system, drawing T cells away from the tumor and into surrounding fibrous tissue. Now, researchers have found that the FDA-approved drug AMD3100 can release these T cells, allowing them to target and attack the cancer more effectively. This breakthrough could greatly enhance the success of immunotherapies against this aggressive form of cancer, offering new hope for patients who currently have limited treatment options. The implications are significant, as it may pave the way for broader applications of this strategy against other cancers that similarly evade immune detection.